Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral hypoglycemic agents for the treatment of T2DM, their mechanism being the inhibition of glucose and sodium reabsorption from the proximal renal tubule, thereby reducing glucose levels in the blood. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.